Aptamer Group Launches Targeted Radiopharmaceutical Program

Aptamer Group plc, nan developer of next‑generation synthetic binders for nan life sciences industry, coming announced nan motorboat of a caller targeted radiopharmaceutical programme successful collaboration pinch Radiopharmium Ltd, a UK-based master consultancy successful radiopharmaceutical development.

Collaboration pinch Radiopharmium Ltd intends to beforehand Optimer®-based radioconjugates, pinch early stableness information suggesting a perchance differentiated floor plan versus peptide comparators. Image Credit: Aptamer Group

A precocious maturation marketplace pinch unmet need

The targeted radiopharmaceuticals marketplace is weighted astatine astir US$7.5 cardinal successful 2025 and represents 1 of oncology’s fastest-growing sectors. Radiopharmaceuticals present a radioactive payload straight to diseased tissue, but a persistent situation is nan degradation of nan targeting molecule erstwhile it carries a radioactive payload, shortening support life, expanding waste, and complicating distribution. The manufacture modular is to adhd protective additives specified arsenic ascorbic acerb to mitigate this degradation.

Optimer® platform: A perchance differentiated stableness profile

Aptamer has antecedently developed afloat integrated radioligand conjugates incorporating proprietary chemistry, linkers, and chelation systems, and evaluated their stableness nether clinically applicable conditions utilizing Ga-68 (Gallium-68) and Lu-177 (Lutetium-177), radioactive isotopes wide utilized successful crab imaging and targeted therapy.

In comparative testing astatine 24 hours, Lu-177 Optimer®-based radioligands demonstrated only 8 % degradation successful nan absence of protective additives, compared pinch 34–83 % degradation seen pinch starring peptide comparators nether nan aforesaid conditions. The institution believes these results whitethorn support extended support life, reduced waste, and simplified logistics, offering a perchance differentiated floor plan comparative to existing approaches.

Program improvement and milestones

Three strategical therapeutic targets, representing high-value objective conditions, person been identified for Optimer® radioconjugate development. The programme will advancement done in vitro validation earlier advancing to in vivo studies assessing targeting and therapeutic performance.

Key programme highlights:

• Three therapeutic targets selected crossed high-value objective indications
• Optimer® radioconjugates to beryllium validated in vitro earlier progressing to in vivo models
• Combined pinch nan existing collaborated programme pinch a apical 3 world pharmaceutical company, nan pipeline is expected to comprise 4 radiotherapy assets
• In vivo information targeted for transportation by extremity of 2026

Expert leadership

The programme will beryllium led by Dr Louis Allott, CEO of Radiopharmium Ltd and a personnel of Aptamer’s Scientific Advisory Board. Dr Allott is simply a recognized master successful radiopharmaceutical development, pinch acquisition spanning laboratory find done to objective translation. He will return a fractional domiciled arsenic Director of Radioligand Development for Aptamer, overseeing radiochemical conjugation and biologic information successful established preclinical models.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:

“We are excited to motorboat this programme successful a high‑growth section wherever nan limitations of existing targeting technologies create a compelling opportunity for our Optimer® platform.

A cardinal situation successful radiopharmaceuticals is maintaining nan stableness of nan targeting molecule erstwhile it is carrying a radioactive payload. Our information indicates that Optimer®-based radioligands whitethorn connection improved stableness compared to existing approaches, which could construe into applicable advantages successful manufacturing, distribution, and objective use, taxable to further validation.

With Louis starring this programme and entree to world-class preclinical models done Radiopharmium, we are well-positioned to beforehand aggregate assets towards successful vivo validation and further show nan imaginable of our level successful this quickly increasing therapeutic field.”

I americium delighted to beryllium moving pinch Aptamer, a recognised leader successful nan section of aptamer exertion pinch a beardown way grounds of success. The operation of Aptamer’s innovative Optimer® level and Radiopharmium’s expertise successful radiopharmaceutical improvement makes this collaboration well‑positioned to show nan imaginable of aptamer‑based targeting successful next‑generation radiopharmaceuticals.”

Dr Louis Allott, Chief Executive Officer, Radiopharmium Ltd